Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials
Headache: The Journal of Head and Face Pain · 2024
DOI: 10.1111/head.14743 ↗At a glance
Klinische Studie (Phase III) in Headache: The Journal of Head and Face Pain, 2024. Written by Stephen D Silberstein and 4 co-authors. Institution: Jefferson Headache Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Major MEDLINE topics: Botulinum Toxins, Type A, Migraine Disorders. Cited 9 times so far (Crossref); 42 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: AbbVie.
Abstract (original language)
Objective To characterize the long‐term (56‐week) benefits of continuous onabotulinumtoxinA treatment response in individuals with chronic migraine (CM) who achieved reduction to
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Jefferson Headache Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
- Department of Neuroepidemiology, Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany.
- Department of Neurology, Mayo Clinic, Phoenix, Arizona, USA.
- Atria Academy of Science and Medicine, New York, New York, USA.
- Allergan, an AbbVie Company, Irvine, California, USA.
- Department of Neurology, Montefiore Headache Center, Albert Einstein College of Medicine, Bronx, New York, USA.
ORCID profiles: David W Dodick, Richard B Lipton
Funding
- AbbVie
Cite
APA
Silberstein, S. D., Diener, H. C., Dodick, D. W., Sommer, K., & Lipton, R. B. (2024). Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14743
Vancouver
Silberstein SD, Diener HC, Dodick DW, Sommer K, Lipton RB. Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials. Headache: The Journal of Head and Face Pain. 2024. doi:10.1111/head.14743
BibTeX
@article{Silberstein2024,
author = {Silberstein, Stephen D and Diener, Hans-Christoph and Dodick, David W and Sommer, Katherine and Lipton, Richard B},
title = {Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials},
journal = {Headache: The Journal of Head and Face Pain},
year = {2024},
doi = {10.1111/head.14743}
}
EUVIMED